trending Market Intelligence /marketintelligence/en/news-insights/trending/flm9zr_y8w96ehqs0enl3a2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Roche's hemophilia therapy Hemlibra gets Japanese approval

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Roche's hemophilia therapy Hemlibra gets Japanese approval

Chugai Pharmaceutical Co. Ltd. said Japan's Ministry of Health, Labour and Welfare approved Hemlibra for treating hemophilia A.

The Japanese drug regulator allowed the use of an injection of Hemlibra, also known as emicizumab, to prevent or reduce bleeding episodes in patients with hemophilia A.

The approval was based on results of the Haven 1 and Haven 2 studies of Hemlibra in patients with hemophilia A.

Hemlibra received approval from the U.S. Food and Drug Administration in November 2017 and from the European Commission in February 2018.

About 5,000 individuals in Japan suffer from hemophilia A, an inherited disorder in which blood does not clot properly, resulting in uncontrolled bleeding.

Chugai is majority owned by Swiss drugmaker Roche Holding AG.